N-Acetyl-D-tryptophan (CAS 2280-01-5), systematically named (2R)-2-acetamido-3-(1H-indol-3-yl)propanoic acid, is released as a white to off-white crystalline powder with the molecular formula C₁₃H₁₄N₂O₃ and molecular weight 246.26 g/mol. The product is the N-acetylated D-enantiomer of tryptophan and is supplied under supplier-specific grade designations because no USP, Ph. Eur., or JP monograph is assigned to this compound. Standard catalogue entries differentiate research grade from custom synthesis intermediate; typical release purities are ≥98.0% and ≥99.0% by HPLC area percent. The free acid is soluble in methanol, ethanol, and dimethyl sulfoxide, and is weakly soluble in water; aqueous solubility increases above pH 8 as the carboxylate forms. Reported melting range values fall between 180 °C and 190 °C, with lot-specific values on the certificate of analysis. The compound is assigned an optical rotation of approximately -30° at c=1 in water, which distinguishes it from the L-isomer.

Because no compendial standard exists, model and specification alignment across suppliers is not uniform. Buyers should request the supplier’s change-control policy, residual solvent profile under ICH Q3C, and elemental impurity data under ICH Q3D when the material is intended for pharmaceutical synthesis. Published data for cGMP-compliant grades of N-acetyl-D-tryptophan is limited.

What Are the Release Specifications and Analytical Reference Points?

Because the material lacks a compendial monograph, the following representative limits are drawn from supplier certificates of analysis and general methods. The values in Table 1 are not compendial requirements; lot-specific certificates govern acceptance.

The HPLC assay method typically uses a C18 column (150 mm × 4.6 mm, 5 µm) maintained at 25 °C with a water/acetonitrile gradient containing 0.1% trifluoroacetic acid and ultraviolet detection at 220 nm. Chiral purity is run separately on a chiral stationary phase; a representative limit for N-acetyl-L-tryptophan is ≤0.5% by area. Water content by Karl Fischer titration per USP <921> is often ≤0.5% even when loss on drying is compliant. Process-related impurities can include D-tryptophan from incomplete acetylation, N-acetyl-L-tryptophan from chiral contamination, and indole-3-acetic acid from oxidative degradation. HPLC methods with UV detection at 220 nm may under-report impurities lacking chromophores; when a full impurity profile is required, orthogonal detection with charged aerosol or evaporative light scattering should be considered. The specification should include a test for D-tryptophan if the material is used in a downstream step where free amine content affects stoichiometry.

In Fmoc-based solid-phase peptide synthesis, Ac-D-Trp-OH is introduced directly without additional α-amine protection because the acetyl group masks the primary amine. Coupling protocols commonly use 2–4 equivalents of the protected amino acid relative to resin substitution, activation with HBTU or HATU and a tertiary amine base in DMF or NMP, and agitation under nitrogen in a jacketed solid-phase reactor. Resin substitution is typically 0.3–0.8 mmol/g for Wang resin. Coupling temperature is maintained at 20–25 °C to minimize racemization. Reaction completion is monitored by Kaiser test; residual free amine after coupling is typically ≤1.0% of initial resin loading as determined by UV spectrophotometric analysis of the Fmoc cleavage product at 301 nm.

Epimerization control is a critical process parameter. During carbodiimide-mediated activation, preactivation of Ac-D-Trp-OH should not exceed 5 minutes at 0–5 °C; extended exposure to tertiary amine bases can promote oxazolone formation and stereochemical erosion. Incoming material should be tested for enantiomeric purity because even 1% of the L-isomer can be significant in chiral drug synthesis, which is tighter than the common 0.5% release limit for some applications. In anhydrous DMF, Ac-D-Trp-OH solutions are typically stable for 24 hours at 4 °C; aqueous solutions above pH 8 should be used immediately due to base-catalyzed acetyl hydrolysis. The compound is not recommended for use with amine-based additives in long-term formulation storage because of potential transamidation or premature cleavage.

For D-tryptophan manufacture, N-acetyl-D-tryptophan is generated as the unhydrolyzed residual enantiomer after L-specific acylase I treatment of N-acetyl-DL-tryptophan. Typical substrate loadings fall in the 50–150 mM range in phosphate-buffered medium at pH 7.5–8.0; acylase I is added at 0.1–1.0 U/mL, and the reaction is maintained at 37 °C. Conversion approaches 50%, and the residual N-acetyl-D-tryptophan can exhibit enantiomeric excess above 99% after extraction or crystallization. The isolated N-acetyl-D-tryptophan is then hydrolyzed under reflux in 2 M aqueous hydrochloric acid for 6–12 hours or with D-aminoacylase at pH 7.5–8.0 to release D-tryptophan. Pilot-scale operations using immobilized acylase in packed-bed reactors have been described; published data for production-scale hydrolysis of the isolated D-enantiomer is limited.

When the D-Enantiomer Must Be Distinguished from the L-Form and the Racemate

N-Acetyl-L-tryptophan (CAS 1218-34-4) rotates plane-polarized light in the positive direction, while N-acetyl-D-tryptophan shows a negative specific rotation of approximately -30° at c=1 in water. The racemate (CAS 87-32-1) exhibits no net rotation. In albumin stabilizer discussions, the racemate is the form typically referenced; substitution with the isolated D-isomer requires formulation-specific pasteurization stability data. Published data comparing stabilizer efficacy of the isolated D-isomer under identical heat-treatment conditions is limited.

The structural identity of all three compounds is identical except for stereochemistry at the α-carbon. Therefore, infrared and ultraviolet spectra are nearly superimposable; differentiation requires chiral HPLC or polarimetry. In synthetic peptide work, the D-isomer is used when the target sequence requires D-tryptophan at the N-terminus or as a chiral probe of stereoselective binding. For pharmaceutical intermediate applications, the D-isomer provides a direct route when the free D-amino acid would require additional α-amine protection.

Because the N-acetyl derivative cannot be selectively removed under standard piperidine Fmoc deprotection conditions, Ac-D-Trp-OH is generally used as an N-terminal residue or as a protected fragment, not as an internal residue in Fmoc-based sequences. D-Tryptophan requires Fmoc protection before insertion into the same synthesis. This difference in protecting-group chemistry determines the choice of reagent in production-scale peptide synthesis.

Storage at 2–8 °C in tightly closed containers under an inert gas is recommended; short-term transport at ambient temperature is acceptable if the container remains sealed and relative humidity is below 60%. The compound is incompatible with strong oxidizing agents and strong bases; the N-acetyl group undergoes hydrolysis at pH > 9 and elevated temperature, releasing D-tryptophan. Prior to use in moisture-sensitive coupling reactions, drying under vacuum at 40 °C until loss on drying is ≤0.5% is recommended. Weighing and charging should be conducted under a dry nitrogen atmosphere when residual water would interfere with activation chemistry.

Regulatory documentation for N-acetyl-D-tryptophan should include residual solvent data under ICH Q3C, elemental impurity data under ICH Q3D, and mutagenic impurity assessment under ICH M7 when used in pharmaceutical synthesis. The material is not assigned a compendial monograph; therefore, supplier-specific certificates of analysis and change-control agreements are the primary quality instruments. Long-term stability data under ICH Q1A conditions for this compound is limited, so accelerated studies should be initiated when the material is used in late-stage clinical manufacturing.

Chiral Purity Determinations Using Immobilized Crown Ether Phases

Enantiomeric excess measurement for N-acetyl-D-tryptophan typically uses chiral stationary phases; crown ether columns such as Crownpak CR-I(+) or equivalent ligand-exchange columns are used with aqueous perchloric acid/acetonitrile mobile phases and detection at 220 nm. The enantiomeric excess is calculated as [(D − L)/(D + L)] × 100%. Method qualification typically verifies resolution between the D- and L-peaks of > 1.5 and a signal-to-noise ratio for the L-isomer at the reporting threshold of ≥10:1. Published data for inter-laboratory reproducibility of N-acetyl-D-tryptophan chiral HPLC methods is limited; therefore, system suitability criteria should be established on each column lot. The method may be cross-checked by polarimetry using USP <781>.